Dear 222 News viewers, sponsored by smileband,
MIT’s “Circulatronics”: injectable brain chips that treat — not “cause” — disease without skull surgery
MIT researchers this month published a paper describing a radical new approach to brain stimulation: billions-of-times-smaller-than-a-grain-of-rice electronic devices that can be injected into the bloodstream, ride to inflamed or diseased brain tissue, and self-implant to deliver targeted electrical therapy — all without opening the skull. The platform, which the team calls Circulatronics, is being hailed as a potential game-changer for conditions currently treated with invasive deep-brain implants, but it’s still early-stage and was demonstrated so far in animals.
What is Circulatronics
At the heart of the system are sub-cellular-sized wireless electronic devices (SWEDs) — microscopic chips built from organic semiconductor layers that harvest energy wirelessly (the team used a photovoltaic approach) and convert that power into tiny electrical pulses. To avoid being cleared by the immune system and to steer them to the right place, the chips are paired with living immune cells to form cell–electronics hybrids. Those hybrids circulate, detect areas of inflammation in the brain’s vasculature, and then lodge themselves at the target site where they can stimulate nearby neurons. The researchers describe the approach and experiments in Nature Biotechnology.
Why this matters
Electrical stimulation of specific brain regions is an effective treatment for a number of disorders — Parkinson’s disease, certain forms of epilepsy, treatment-resistant depression and chronic pain are examples — but today’s methods usually require neurosurgery to implant electrodes. Surgery adds cost, risk of infection, and limits who can access these therapies. Circulatronics promises a surgery-free route to focal neuromodulation by replacing a skull operation with a simple intravenous injection. If translated to humans, that could dramatically broaden access to targeted brain therapies.
What the team has actually shown
The work is not hypothetical — the paper reports experiments in rodents showing that the SWED + immune-cell hybrids can home to inflamed brain regions, self-implant, be powered externally, and deliver neuromodulatory stimulation that reduces markers of neuroinflammation in the animal models used by the team. That’s an important proof-of-principle, but it is preclinical: safe, effective human use is not yet demonstrated. The authors emphasize many technical, safety and regulatory hurdles remain before people could receive such devices.
Potential applications — and limits
The MIT team lists a wide range of neurological conditions that might benefit from focal stimulation of inflamed or dysfunctional brain tissue: Alzheimer’s disease, multiple sclerosis, ischemic stroke, certain tumors, neuropathic pain and more. Yet several critical questions must be answered before clinical rollout is realistic:
• Targeting & control: Can the devices be reliably guided to the correct brain region in humans and stay there without migrating?
• Safety & immune response: Do the cell–electronics hybrids provoke unintended immune reactions, clots, or off-target effects?
• Power & lifetime: How will the devices be powered safely and for how long — hours, months, years?
• Removal & reversibility: If something goes wrong, can the devices be removed or safely neutralized?
• Long-term biocompatibility: Are there chronic effects of having many tiny electronics lodged in brain tissue?
Researchers and regulators will require extensive additional animal studies, large-animal testing and tightly controlled early human trials before the technology could be cleared for medical use.
Ethical, regulatory and societal concerns
A technology that enables autonomous, invisible implants raises familiar but acute ethical concerns: informed consent, surveillance or misuse, equity of access, and governance around modifications to cognition or mood. The MIT paper and coverage around it note those issues; ethicists will be closely watching the field as it progresses. Transparent clinical trial design, independent oversight and public engagement will be essential if Circulatronics moves toward human use.
Bottom line
MIT’s Circulatronics is a striking scientific advance: tiny, injectable, cell-carried electronics that can self-implant and deliver focal brain stimulation — demonstrated in animals and described in Nature Biotechnology. It is designed to treat neurological disease without brain surgery, not to cause disease. But it is early research, not an available therapy: important technical, safety, ethical and regulatory hurdles remain before it could be offered to patients. For now it’s a promising new direction in bioelectronics that will require careful, stepwise development and oversight.
Sources & further reading: MIT News coverage of the work; the Nature Biotechnology paper describing “Circulatronics”; in-depth reporting by New Atlas and news outlets summarizing the team’s preclinical findings and potential.
Attached is a News article regarding MIT chip that can implanted in to the body to cure disease
https://interestingengineering.com/health/injectable-brain-implants-mit
Article written and configured by Christopher Stanley
In-- Google tag (gtag.js) --> <script async src="https://www.googletagmanager.com/gtag/js?id=G-XDGJVZXVQ4"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-XDGJVZXVQ4'); </script>
<script src="https://cdn-eu.pagesense.io/js/smilebandltd/45e5a7e3cddc4e92ba91fba8dc
No comments:
Post a Comment